ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Intrinsic resistance and RTK-RAS-MAPK pathway reactivation has limited the effectiveness of MEK and RAF inhibitors (MAPKi) in RAS- and RAF-mutant cancers. To identify genes that modulate sensitivity to MAPKi, we performed genome-scale CRISPR-Cas9 loss-of-function screens in two KRAS mutant pancreatic cancer cell lines treated with the MEK1/2 inhibitor trametinib. Loss of CIC, a transcriptional repressor of ETV1, ETV4, and ETV5, promoted survival in the setting of MAPKi in cancer cells derived from several lineages. ATXN1L deletion, which reduces CIC protein, or ectopic expression of ETV1, ETV4, or ETV5 also modulated sensitivity to trametinib. ATXN1L expression inversely correlates with response to MAPKi inhibition in clinical studies. These observations identify the ATXN1L-CIC-ETS transcription factor axis as a mediator of resistance to MAPKi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 3×
“Screening was performed using a lentivirally delivered two-vector CRISPR-Cas9 system (Doench et al., 2016; Shalem et al., 2014).”
MethodSelf-citationEasy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390 · cited 2×
“We generated ATXN1LKO cells and assessed the efficiency of ATXN1L knockout by TIDE (Tracking of Indels by DEcomposition, Brinkman et al., 2014), a method to quantify the frequency of mutations induced by CRISPR-Cas9, as we were unable to identify an ATXN1L-specific antibody for immunoblotting (Figure S7).”
MethodDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“Although the majority of cancers with mutant RAS depend on oncogenic RAS signaling for proliferation and survival, direct inhibitors of oncogenic RAS proteins have not yet been developed for clinical use (Chien et al., 2006; Cox et al., 2014; Stephen et al., 2014).”
BackgroundVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“Early clinical trials suggest that a subset of KRAS- or BRAF-mutant cancers respond to small molecule inhibitors of MEK or BRAF, though both intrinsic and acquired resistance limit therapeutic efficacy (Blumenschein et al., 2015; Chapman et al., 2011; Hyman et al., 2015; Infante et al., 2012).”
BackgroundCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citationRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 3×
“…NF1 inactivation (Whittaker et al., 2013); or increased NRAS (Nazarian et al., 2010), A/B/C-RAF (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2011; Thakur et al., 2013; Villanueva et al., 2010), COT (Johannessen et al., 2010), or MEK1/2 activity (Nikolaev et al., 2011;…”
BackgroundCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“Although the majority of cancers with mutant RAS depend on oncogenic RAS signaling for proliferation and survival, direct inhibitors of oncogenic RAS proteins have not yet been developed for clinical use (Chien et al., 2006; Cox et al., 2014; Stephen et al., 2014).”
BackgroundDifferential regulation of MAP kinase signalling by dual-specificity protein phosphatases
Owens, D. M., & Keyse, S. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210412 · Cited by 777 · cited 1×
“…signaling induces the expression of SPRY and SPRY-related proteins with an EVH1 domain (SPRED) proteins (Kim and Bar-Sagi, 2004), which inhibit MAPK signaling at multiple levels of the pathway, as well as DUSP phosphatases (Owens and Keyse, 2007), which directly dephosphorylate and inhibit ERK1/2.”
BackgroundDuncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · cited 2×
“Preclinical and clinical studies have shown that a major mode of intrinsic and acquired resistance to MEK or BRAF inhibitor monotherapy in RAS- or BRAF-mutant cancers is the reactivation of the RTK-RAS-MAPK pathway by mechanisms (Caunt et al., 2015; Lito et al., 2013), such as loss of feedback inhibition (Corcoran et…”
BackgroundTumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585 · cited 2×
“…MEK or BRAF inhibitor monotherapy in RAS- or BRAF-mutant cancers is the reactivation of the RTK-RAS-MAPK pathway by mechanisms (Caunt et al., 2015; Lito et al., 2013), such as loss of feedback inhibition (Corcoran et al., 2012; Duncan et al., 2012); upregulated RTK signaling (Nazarian et al.,…”
BackgroundInfante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · cited 1×
“…acquired resistance mechanisms to MAPK pathway inhibitor therapy that have been identified in patients with RAF-mutant cancers involve upregulation of MAPK pathway signaling upstream of ERK (Long et al., 2014; Rizos et al., 2014; Shi et al., 2014; Van Allen et al., 2014; Wagle et al., 2011; 2014).”
BackgroundA melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature · doi:10.1038/nature12688 · Cited by 452
Self-citationLong, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375 · cited 6×
“The majority of acquired resistance mechanisms to MAPK pathway inhibitor therapy that have been identified in patients with RAF-mutant cancers involve upregulation of MAPK pathway signaling upstream of ERK (Long et al., 2014; Rizos et al., 2014; Shi et al., 2014; Van Allen et al., 2014; Wagle et al., 2011; 2014).”
BackgroundMethodInfluentialBlumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
ATAXIN-1 Interacts with the Repressor Capicua in Its Native Complex to Cause SCA1 Neuropathology
Lam, Y. C., Bowman, A. B., Jafar-Nejad, P., Lim, J., Richman, R., Fryer, J. D., Hyun, E. D., Duvick, L. A., Orr, H. T., Botas, J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.038 · Cited by 326
Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302 · cited 1×
“The RAF-MEK-ERK (MAPK) pathway is an important downstream effector of oncogenic RAS (Blasco et al., 2011; Collisson et al., 2012).”
BackgroundCrespo-Barreto, J., Fryer, J. D., Shaw, C. A., Orr, H. T., & Zoghbi, H. Y. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001021 · Cited by 136 · cited 6×
“…by Reducing CIC Protein In mice, ATXN1L has been shown to form a complex with CIC and increase CIC protein expression (Bowman et al., 2007; Crespo-Barreto et al., 2010; Lee et al., 2011), and ATXN1L has been implicated as a co-repressor that synergistically enhances CIC transcriptional…”
BackgroundInfluential
Cited by
Am I ready for CRISPR? A user's guide to genetic screens
Doench, J. G. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.97 · Cited by 452
Self-citationTranscriptomic definition of molecular subgroups of small round cell sarcomas
Watson, S., Perrin, V., Guillemot, D., Reynaud, S., Coindre, J., Karanian, M., Guinebretière, J., Freneaux, P., Le Loarer, F., Bouvet, M., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5053 · Cited by 335
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251
Shirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108532 · Cited by 123
Self-citation
Metadata
- Authors
- Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicinska, E., Sulahian, R., Goodale, A., Cowley, G. S., Piccioni, F., Doench, J. G., Root, D. E., & Hahn, W. C.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 18
- Issue
- 6
- Pages
- 1543-1557
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2586467231
- Cited by
- 128
- References
- 24
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.